Independent editorial coverage · not a pharmacy
← All policy coverage
ExplainerOctober 25, 2025 · 6 min read

Biosimilar vs. Generic: Which Approval Pathway Applies to GLP-1 Drugs, Explained

Semaglutide and tirzepatide are peptides of 40 or fewer amino acids, so in the U.S. they are approved as drugs, and copies go through the generic (ANDA) pathway rather than the biosimilar route used for insulin. Here's the difference.

By the GLP Semaglutide editorial team · Last updated October 25, 2025

Two identical vials side by side under laboratory lighting
Photo illustration

U.S. law has two separate routes for lower-cost copies of brand-name medicines. Generic drugs are approved through an abbreviated new drug application (ANDA), mainly by showing the same active ingredient and bioequivalence to the reference drug. Biosimilars are approved under section 351(k) of the Public Health Service Act and must show they are highly similar to a licensed biological product, with no clinically meaningful differences in safety, purity, and potency. Which route applies depends on how the original product is regulated.

Where the 40-amino-acid line falls

FDA regulations at 21 CFR 600.3 define a protein as an amino acid polymer with a specific, defined sequence that is greater than 40 amino acids in size. Proteins are regulated as biological products; peptides of 40 or fewer amino acids are not, and remain drugs under the Federal Food, Drug, and Cosmetic Act. Semaglutide, tirzepatide, and liraglutide all fall under that threshold. Their brand products, including Ozempic, Wegovy, Mounjaro, and Zepbound, are approved under new drug applications (NDAs), so copies are reviewed as generics through ANDAs, not as biosimilars.

Generic liraglutide shows the pathway in practice: the FDA announced the first generic approval for a once-daily GLP-1 injection in December 2024. In July 2026 the agency published revised draft product-specific guidances for generic peptide products, including semaglutide and tirzepatide, covering topics such as impurity thresholds, immune response testing, and higher order structure.

Insulin is the contrast case

Insulin used to be approved under NDAs as well. Under the Biologics Price Competition and Innovation Act, insulin and other protein products approved as drugs were deemed to be biologics licenses on March 23, 2020. Since then, follow-on insulins are reviewed as biosimilars under the 351(k) pathway. The FDA has noted that this transition does not affect peptides of 40 or fewer amino acids, which is why GLP-1 drugs did not move with insulin.

Why this matters for GLP-1 competition

Being on the generic pathway does not make GLP-1 copies simple to approve. Peptides are more complex than most small-molecule drugs, and the FDA's draft guidance asks applicants to address impurities and possible immune responses in addition to sameness and bioequivalence. Patents and regulatory exclusivity also limit when an ANDA can be approved, so timing is likely to vary from product to product.

Substitution works differently on each pathway

For biosimilars, such as follow-on insulins, a separate 'interchangeable' designation is generally what allows a pharmacist to substitute the product without new prescriber sign-off, subject to state law. Generic drugs approved through an ANDA work differently: when the FDA rates a generic as therapeutically equivalent to the brand, state pharmacy laws generally permit substitution without a separate interchangeability step.

Correction

An earlier version of this article said that semaglutide and tirzepatide copies would go through the biosimilar pathway. That was incorrect. Under U.S. rules they are drugs approved under NDAs, and their copies follow the generic (ANDA) pathway. The article was corrected on October 23, 2026.

#biosimilar#generic#anda#fda pathway#explainer
This article is for general information only and is not medical advice. Consult a licensed healthcare provider before making any decisions about GLP-1 medications.